Platform
CurieCoreTech In vivo preclinical experiments
Thematic areas of research:
Image
© Benoit Rajau / Institut Curie
To top
Platform
DIDIER DECAUDIN
CurieCoreTech In vivo preclinical experiments
Cancer treatment is continuously evolving with many potential medications being developed. However, clinical trials are costly, time-consuming, and expose patients to side effects. Without prior preclinical evaluation, the ethics, feasibility, and economics of conducting them would be questionable. Preclinical investigation of anti-tumor compounds on tumor models is an important step in the process of drug development. To obtain preclinical results with high predictive value for clinical trials, the choice of the preclinical tumor model(s) is a crucial point.
Members
Image
Image
Image
Image
Our works
Key publications
All publications
-
-
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancersScience Translational Medicine
-
News
All news